Revision of the Drug Price Standard and Healthcare Insurance System Reform
First written in FY2016. 26 of 29 entries say "Materialised", first in FY2017-Q1. Latest entry: 2026-08-05.
Toho Holdings moved to the "Worse" side of this theme in 2016, 4 years before the typical company in this theme (2020).
The whole theme swung hardest in 2018: 20 of 65 companies on the "Worse" side.
17 other companies' latest entry also says "Materialised".
- FY2026-H1MaterialisedAnnual report
「In the pharmaceutical industry, an interim-year drug price revision covering 53% of all products was implemented in April, along with special applications of recalculations for unprofitable products and an increase in minimum drug prices.」
The April 2025 interim-year drug price revision was implemented for 53% of all products, and recalculations for unprofitable products and an increase in minimum drug prices were also carried out. The risks associated with drug price and healthcare system revisions have materialised in the actual business environment. - FY2025-H1MaterialisedAnnual report
「The prescription pharmaceutical market in the six-month consolidated accounting period posted positive growth. Although the official drug price schedule was reduced by 4.67% on a drug-cost basis under the drug price revision implemented in April 2024, and sales of COVID-19-related products declined following the end of public funding for COVID-19 treatments, growth in new drugs, including cancer treatments, specialty products and vaccines supported the market.」
The 4.67% reduction on a drug-cost basis under the April 2024 drug price revision and the decline in sales of COVID-19-related products materialised. Meanwhile, the market posted positive growth due to the expansion of new drugs, specialty products and vaccines. - FY2024MaterialisedAnnual report
「The business continued to be affected by measures to contain healthcare costs, including the implementation of an interim-year drug price revision in April 2023.」
The interim-year drug price revision was implemented in April 2023, and the impact of healthcare cost-containment measures on the market and earnings materialised in the business environment for the full year. - FY2024-Q1MaterialisedAnnual report
「The prescription pharmaceutical market in the first quarter continued to be affected by healthcare cost-containment measures, including the implementation of an interim-year drug price revision in April 2023.」
The interim-year drug price revision was implemented in April 2023, and the risks associated with revisions to the official drug price schedule and healthcare cost-containment measures materialised in the business environment for the quarter. - FY2023-Q1MaterialisedAnnual report
「The prescription pharmaceutical market in the first quarter continued to be affected by healthcare cost-containment measures, including a 6.69% reduction in the official drug price schedule on a drug-cost basis under the medical fee revision implemented in April 2022. However, the market posted positive growth due to the expansion of new drugs, including cancer treatments, and specialty pharmaceuticals, as well as an improvement in patients’ tendency to refrain from visiting medical institutions.」
The official drug price schedule was reduced by 6.69% on a drug-cost basis under the medical fee revision in April 2022, and the risk of institutional revisions materialised in the actual business environment. Meanwhile, the market posted positive growth due to the expansion of new drugs and specialty pharmaceuticals. - FY2022-Q2MaterialisedAnnual report
「The prescription pharmaceutical market in the second quarter was affected by the interim-year drug price revision first implemented in April 2021. However, the decline in patients’ visits to medical institutions was on a recovery trend, partly due to the widespread rollout of COVID-19 vaccinations, and the market posted positive growth.」
The interim-year drug price revision was implemented for the first time in April 2021, reaffirming that its impact on the prescription pharmaceutical market had materialised. - FY2022-Q1MaterialisedAnnual report
「During the first quarter, the first drug price revision in an interim year was implemented in April 2021 in the prescription pharmaceutical market.」
The first drug price revision in an interim year was implemented in April 2021, and the risk associated with revisions to the National Health Insurance Drug Price Standard emerged in the actual business environment. - FY2021-Q3MaterialisedAnnual report
「During the third quarter, the prescription pharmaceutical market continued to operate in a challenging environment due to the impact of the April 2020 drug price revision and healthcare cost-containment measures, including the promotion of generic drug use, as well as the renewed increase in patients refraining from seeking medical care because of concerns about infection risk amid the further spread of COVID-19, described as the third wave.」
The company stated that the impact of the April 2020 drug price revision, healthcare cost-containment measures and patients refraining from seeking medical care continued into the third quarter and that the market remained in a challenging environment. - FY2021-Q2MaterialisedAnnual report
「During the second quarter, the prescription pharmaceutical market continued to operate in a challenging environment due to the impact of the April 2020 drug price revision and healthcare cost-containment measures, including the promotion of generic drug use, as well as the suspension of sales activities accompanying the spread of COVID-19 and patients refraining from seeking medical care due to concerns about the risk of infection.」
The company stated that the April 2020 drug price revision, measures to promote generic drug use, the suspension of sales activities and patients refraining from seeking medical care actually affected the prescription pharmaceutical market during the second quarter. - FY2021-Q1MaterialisedAnnual report
「During the first quarter, the prescription pharmaceutical market remained in a challenging environment due to the impact of the April 2020 drug price revision and healthcare cost-containment measures, including the promotion of generic drug use, as well as patients refraining from seeking medical care due to concerns about the risk of COVID-19 infection, which forced domestic and overseas economic activity to stagnate, and the suspension of sales activities under the state of emergency.」
The company stated that the April 2020 drug price revision, measures to promote generic drug use and patients refraining from seeking medical care actually affected the prescription pharmaceutical market during the first quarter. - FY2020MaterialisedAnnual report
「The company continued to operate in a challenging environment, including the implementation of a drug price revision accompanying the consumption tax rate increase in October 2019 and a 2.40% reduction in the National Health Insurance Drug Price Standard.」
The drug price revision accompanying the consumption tax rate increase and the 2.40% reduction in the National Health Insurance Drug Price Standard were implemented, and the institutional reform risk actually emerged in the business environment for the full fiscal year. - FY2020-Q3MaterialisedAnnual report
「During the third quarter, a drug price revision accompanying the consumption tax rate increase was implemented in October 2019, including a 2.40% reduction in the National Health Insurance Drug Price Standard. Although the company was affected by the drug price revision, performance remained solid due to growth in sales of new drugs such as cancer treatments, specialty pharmaceuticals and orphan drugs, as well as expansion of customer support systems, including initial consultation reception services.」
The company stated that the drug price revision accompanying the consumption tax rate increase and the 2.40% reduction in the National Health Insurance Drug Price Standard were implemented and that it was also affected by the drug price revision. At the same time, it said performance remained solid due to growth in sales of new drugs and specialty pharmaceuticals, among others. - FY2020-Q2MaterialisedAnnual report
「During the second quarter, the prescription pharmaceutical market recorded positive growth despite the impact of healthcare cost-containment measures, including the promotion of generic drug use, supported by growth in new drugs and the impact of front-loaded demand resulting from the drug price revision accompanying the consumption tax rate increase implemented on 1 October 2019.」
The company stated that, in addition to the impact of healthcare cost-containment measures, the drug price revision accompanying the consumption tax rate increase and the resulting front-loaded demand actually affected the prescription pharmaceutical market and the company's performance. - FY2020-Q1MaterialisedAnnual report
「During the first quarter, the prescription pharmaceutical market continued to operate in a challenging environment due to the promotion of healthcare cost-containment measures, including the promotion of generic drug use.」
The company stated that healthcare cost-containment measures, including the promotion of generic drug use, continued and that the prescription pharmaceutical market remained in a challenging environment. - FY2019WorsenedAnnual report
「A revision to drug prices accompanying the consumption tax increase is scheduled for October this year, and the regular drug price revision will also be implemented in April 2020. In addition, the fundamental reform of the drug pricing system in April 2018 resulted in the decision to introduce drug price surveys and revisions in interim years from April 2021. Depending on the content of future revisions to the National Health Insurance Drug Price Standard and reforms to the health insurance system, including these changes, the reforms may affect the performance of the group.」
The company continues to indicate the potential impact on performance from the frequency of revisions and future institutional changes, specifically citing drug price revisions in October 2019, April 2020 and April 2021. - FY2019-Q3MaterialisedAnnual report
「During the third quarter, the prescription pharmaceutical market continued to operate in a challenging environment, including the implementation of a 7.48% reduction in the National Health Insurance Drug Price Standard, based on drug prices, as part of the April 2018 revisions to medical service fees and partly reflecting the review of the premium for new drug creation and other measures under the fundamental reform of the drug pricing system.」
Revisions to medical service fees, the fundamental reform of the drug pricing system and a 7.48% reduction in the National Health Insurance Drug Price Standard were implemented, and the institutional reform risk continued to emerge in the business environment during the quarter. - FY2019-Q2MaterialisedAnnual report
「During the second quarter, the prescription pharmaceutical market continued to operate in a challenging environment, including the implementation of a 7.48% reduction in the National Health Insurance Drug Price Standard, based on drug prices, as part of the April revisions to medical service fees and partly reflecting the review of the premium for new drug creation and other measures under the fundamental reform of the drug pricing system.」
Revisions to medical service fees, the fundamental reform of the drug pricing system and a 7.48% reduction in the National Health Insurance Drug Price Standard were implemented, and the institutional reform risk actually emerged in the business environment during the quarter. - FY2019-Q1MaterialisedAnnual report
「Medical service fees were revised in April, and the company continued to operate in a challenging environment, including the implementation of a 7.48% reduction in the National Health Insurance Drug Price Standard, based on drug prices, partly reflecting the review of the premium for new drug creation and other measures under the fundamental reform of the drug pricing system.」
The fundamental reform of the drug pricing system, revisions to medical service fees and a 7.48% reduction in the National Health Insurance Drug Price Standard were implemented, and the institutional reform risk actually emerged in the business environment during the quarter. - FY2018WorsenedAnnual report
「The fundamental reform of the drug pricing system in April 2018 introduced annual drug price surveys and annual revisions to drug prices. Depending on the content of future revisions to the National Health Insurance Drug Price Standard and reforms to the health insurance system, including these changes, the reforms may affect the performance of the group.」
The company stated that annual drug price surveys and revisions would be introduced, replacing the previous two-year revision cycle, thereby increasing the frequency of and potential impact from institutional reform risks. - FY2018-Q3MaterialisedAnnual report
「The prescription pharmaceutical market remained in a challenging environment during the nine-month period ended 31 December due to continued healthcare cost-containment measures, including the promotion of generic drug use. The company was significantly affected by the contraction of the hepatitis C treatment market, although」
The company stated that the challenging market environment caused by continuing healthcare cost-containment measures and the contraction of the hepatitis C treatment market actually occurred and affected its performance. - FY2018-Q2MaterialisedAnnual report
「The prescription pharmaceutical market recorded negative growth in the six-month period ended 30 September, continuing the trend from the previous fiscal year. The company also recorded negative growth as a result of the substantial contraction in the hepatitis C treatment market from the same period of the previous fiscal year.」
The company stated that negative growth in the prescription pharmaceutical market and the substantial contraction in the hepatitis C treatment market actually occurred and affected the company's negative growth. - FY2018-Q1MaterialisedAnnual report
「In the first quarter, the prescription pharmaceutical market contracted 3.2% year on year. In contrast, due to lower sales of hepatitis C treatments, the company's year-on-year decline was greater than the market average.」
The company stated that the 3.2% year-on-year decline in the prescription pharmaceutical market and lower sales of hepatitis C treatments actually contributed to its year-on-year revenue decline. - FY2017MaterialisedAnnual report
「Although new drugs such as anticancer drugs contributed, the company recorded substantially negative growth year on year due to the impact of continued measures to contain healthcare costs, including a 7.8% reduction in the National Health Insurance Drug Price Standard, including the special rule for market expansion repricing in April 2016, and revisions to medical service fees to promote further use of generic drugs, as well as the rapid contraction of the hepatitis C treatment market, which had grown rapidly in the previous fiscal year.」
The company stated that the 7.8% reduction in the National Health Insurance Drug Price Standard, revisions to medical service fees and the contraction of the hepatitis C treatment market actually affected the market and full-year performance. - FY2017-Q3MaterialisedAnnual report
「In the dispensing pharmacy business, the company was affected by the drug price and pharmacy reimbursement revisions implemented in April 2016. Although cost-reduction measures, including standardizing store operations and consolidating operations at headquarters, were implemented, selling, general and administrative expenses increased because of delays in improving productivity.」
The company stated that the impact of revisions to drug prices and dispensing fees continued to affect the dispensing pharmacy business and that selling, general and administrative expenses increased despite the implementation of cost-cutting measures. - FY2017-Q2MaterialisedAnnual report
「Amid the advancement of measures to contain healthcare costs, including a 7.8% reduction in official drug prices, including the special measure for market expansion repricing implemented in April this year, and revisions to medical fees to promote further use of generic medicines」
The company stated that the 7.8% reduction in the National Health Insurance Drug Price Standard and delays in adapting to revisions to dispensing fees led to lower earnings and higher expenses in the dispensing pharmacy business, indicating that the impact of drug price and institutional revisions continued to emerge. - FY2017-Q1MaterialisedAnnual report
「Measures to contain healthcare costs continued to be promoted, including a 7.8% reduction in the National Health Insurance Drug Price Standard, including the special rule for market expansion repricing in April 2016, and revisions to medical service fees to promote further use of generic drugs.」
The company stated that the 7.8% reduction in the National Health Insurance Drug Price Standard and revisions to dispensing fees caused the dispensing pharmacy business to post an operating loss. The existing risk from revisions to the drug price standard had an actual impact on the business in the quarter. - FY2016First statedAnnual report
「Depending on developments in the government's institutional reforms aimed at improving the financial sustainability of the health insurance system, the reforms may affect the performance of the group.」
The National Health Insurance Drug Price Standard is revised every 2 years, and the company identifies developments in health insurance system reform as a risk that may affect performance.